48,877
edits
Difference between revisions of "Ancillary testing in prostate cancer"
Jump to navigation
Jump to search
Ancillary testing in prostate cancer (view source)
Revision as of 15:09, 1 November 2022
, 15:09, 1 November 2022no edit summary
| Line 1: | Line 1: | ||
'''Ancillary testing in prostate cancer''' is evolving. ''Prostate cancer panel'' redirect here. | '''Ancillary testing in prostate cancer''' is evolving. ''Prostate cancer panel'' redirect here. | ||
==PARP inhibitors== | |||
*Poly(ADP-ribose) polymerases (PARP) inhibitors, e.g. olaparib, target BRCA1/2 mutations.<ref name=pmid28250726>{{cite journal |authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A |title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |journal=Prz Menopauzalny |volume=15 |issue=4 |pages=215–219 |date=December 2016 |pmid=28250726 |pmc=5327624 |doi=10.5114/pm.2016.65667 |url=}}</ref> | |||
Molecular panel: | |||
*BRCA1 | |||
*BRCA2 | |||
*ATM | |||
*PALB2 | |||
==See also== | ==See also== | ||